Liraglutide U.S. label context · version 1
This page preserves this version's wording and source pins. Open the current profile →
What does the U.S. product label say?
Liraglutide injection for weight management · Read September 15, 2026 · Preserved label summary 1
Which population and use does the label cover?
The cited generic injection label covers long-term weight reduction alongside diet and activity in adults with obesity or overweight with a weight-related condition, and children aged twelve years and older with obesity and body weight above 60 kg. It does not establish the scope of every liraglutide product. Label: 1 ↗
Which safety limits matter?
The boxed warning reports thyroid C-cell tumors in rodents, with uncertain human relevance. Contraindications include personal or family medullary thyroid carcinoma, MEN 2 and hypersensitivity. Other warnings address pancreatitis, gallbladder disease, hypoglycemia, increased heart rate, kidney injury from volume depletion, severe gastrointestinal reactions and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Liraglutide injection, solution · SPL version 6 · published 2026-07-14
Label ZIP SHA-256: 48d493b4dc6af7d7574aedf0a2f7ab6235a9ed62875baffe6c484b5433647541. Extracted XML SHA-256: 26e94f7191fa24c8a25945ac1cd23ef4a95e897a8c9e84520043a4d7ff6edbef.